At a glance
ClinicalIndex Comparison RecordN/ACompleted· 297 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Study to Assess the Nasopharyngeal Carriage of Streptococcus Pneumoniae (SPn), Long Term Safety and Immune Persistence in Healthy Kenyan PCV-Primed Toddlers (12-15 Months of Age) Who Received a Whole Cell Pneumococcal Vaccine (PATH-wSP) Compared to Controls
In Brief
An observational study for Pneumococcal Disease. Completed, enrolled 297 participants across 1 site.
Detailed Summary
This study evaluated the change in nasopharyngeal carriage (NPC) of Streptococcus pneumoniae (SPn), hypothesizing that it would be reduced post-vaccination with Streptococcus pneumoniae whole cell vaccine with aluminum hydroxide adjuvant (PATH-wSP) and that PATH-wSP would remain safe and well-tolerated over the course of the study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesKenya
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartSep 2014
Primary CompletionFeb 2016
TodayJul 2026
First PostedMay 23, 2014
Enrollment StartSep 25, 2014
Primary CompletionFeb 18, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.1 years ago